Ophthalmic solutions for canine, feline & equine glaucoma and oht
OwnerStephen Douglas Barrett, Mitchell DE LONGinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides an ophthalmic composition comprising ING or KMN-159 and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Claims23
An ophthalmic composition for dogs, cats and horses, comprising:
- a selective EP2 or EP4 agent and
- a carrier.
An ophthalmic composition for dogs, cats and horses, comprising:
- ING or KMN-159;
- and
- about 0.01% weight/volume of a tonicity agent.
An ophthalmic composition for dogs, cats and horses, comprising:
- ING or KMN-159;
- and
- about 0.0001% weight/volume to about 1.0% weight/volume of an FP agent or netarsudil;
- and
- about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
A method for treating glaucoma, ocular hypertension (OHT) and other ophthalmic diseases in an animal in need thereof, the method comprising administering a therapeutically effective amount of a composition comprising a selective EP2 and/or EP4 agent as a free acid, pharmaceutically acceptable salts, its lower alkyl esters, or diastereomers thereof, and an excipient, diluent or carrier.
A method for treating glaucoma, ocular hypertension (OHT) and other ophthalmic diseases in an animal in need thereof, the method comprising administering a therapeutically effective amount of a composition comprising at least one active agent selected from:
- isopropyl N-(6-(((4-(1H-pyrazol-1-yl)benzyl) (3-pyridinylsulfonyl)amino)methyl)-2-pyridinyl)glycinate (ING) and (7-((R)-3,3-difluoro-5-((3S,4S,E)-3-hydroxy-4-methylnon-1-en-6-yn-1-yl)-2-oxopyrrolidin-1-yl) heptanoic acid (KMN-159) including its free acid, pharmaceutically acceptable salts, its lower alkyl esters, or diastereomers thereof;
- and a tonicity agent.
Dependencies are inferred from the claim text.